There has been only marginal improvement in guideline-directed medical therapy uptake and mortality for US Veterans with recent-onset HFrEF from 2013 to 2019, highlighting an urgent need for new implementation strategies.
This study found only marginal improvement between 2013 and 2019 in the guideline-recommended therapy and mortality rates among patients with recent-onset HFrEF. New approaches to increase the uptake of evidence-based HFrEF treatment are urgently needed and could lead to larger reductions in mortality.
Sandhu et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: